Goldman Sachs
LPCN icon

Goldman Sachs’s Lipocine LPCN Stock Holding History

Goldman Sachs’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,527
Closed -$21K – 6426
2022
Q2 		$21K Sell
1,527
-3,686
-71% -$57.4K ﹤0.01% 6160
2022
Q1 		$121K Buy
5,213
+4,378
+524% +$91.6K ﹤0.01% 6043
2021
Q4 		$14K Buy
+835
New +$15.5K ﹤0.01% 6393
2021
Q1 		– Sell
-3,401
Closed -$79K – 6224
2020
Q4 		$79K Buy
+3,401
New +$81.9K ﹤0.01% 5328
2020
Q3 		– Sell
-1,227
Closed -$26K – 5453
2020
Q2 		$26K Buy
+1,227
New +$15.9K ﹤0.01% 5114
2017
Q3 		– Sell
-4,385
Closed -$300K – 6765
2017
Q2 		$300K Buy
+4,385
New +$286K ﹤0.01% 5510
2016
Q2 		– Sell
-1,890
Closed -$326K – 7150
2016
Q1 		$326K Buy
1,890
+1,202
+175% +$205K ﹤0.01% 5187
2015
Q4 		$151K Sell
688
-453
-40% -$95K ﹤0.01% 5905
2015
Q3 		$229K Sell
1,141
-112
-9% -$25.9K ﹤0.01% 5881
2015
Q2 		$183K Sell
1,253
-43
-3% -$5.34K ﹤0.01% 6210
2015
Q1 		$152K Sell
1,296
-34
-3% -$3.7K ﹤0.01% 6198
2014
Q4 		$119K Sell
1,330
-225
-14% -$19K ﹤0.01% 6500
2014
Q3 		$162K Buy
+1,555
New +$193K ﹤0.01% 6321

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs's LPCN Position: Q3 2022 in Review

Goldman Sachs sold out of Lipocine (LPCN) in Q3 2022, closing a stake of 1,527 shares — an estimated $21K sold.

Goldman Sachs first reported a position in LPCN in Q3 2014 and held it in 13 quarters. The position peaked at $326K in Q1 2016. 46 funds tracked by Wall St. Rank hold LPCN as of Q3 2022.

  • Goldman Sachs reported no remaining Lipocine position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,527 Lipocine shares in Q3 2022, an estimated $21K.
  • Goldman Sachs first reported a position in Lipocine in Q3 2014 and held it in 13 quarters.
  • Goldman Sachs's Lipocine position peaked at $326K in Q1 2016.
  • 46 funds tracked by Wall St. Rank held Lipocine as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.